Prediction of ovarian response using the automated Elecsys anti-Mullerian hormone assay in gonadotrophin-releasing hormone antagonist cycles.

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Zuzuarregui, Jose
- Iliodromiti, Stamatina
- Nelson, Scott M.
Grupos
Abstract
RESEARCH QUESTION: What is the capability of serum anti-Müllerian hormone (AMH) measured using the automated Elecsys® AMH immunoassay to (Roche Diagnostics International Ltd) determine ovarian response after fertility treatment? DESIGN: Single-centre, retrospective, observational, cohort study including women undergoing ovarian stimulation. Serum AMH concentrations were determined using the Elecsys AMH immunoassay based on one blood sample drawn 6 months or less before treatment. Stimulation was conducted in accordance with a gonadotrophin-releasing hormone (GnRH) antagonist protocol. Patients were divided into four ovarian response categories based on their oocyte yield: low (0-3), suboptimal (4-9), optimal (10-15) and high (>15). Areas under the curve were calculated for each ovarian response group. RESULTS: Overall, 1248 patients were enrolled. The AMH concentration had a strong positive correlation with oocyte yield (Spearman's rho?=?0.74, P < 0.001). Areas under the curve (95% CI) for AMH predicting ovarian response were 0.85 (0.83 to 0.88) for low and 0.89 (0.87 to 0.91) for high response. Optimal serum AMH cut-offs for predicting a low and high response using the Elecsys AMH immunoassay were 6.4 pmol/l (0.89 ng/ml) and 14.2 pmol/l (1.99 ng/ml), respectively. Multivariable regression analysis showed that 47% (R(2)?=?0.470) of variation in ovarian response could be attributed to AMH alone, increasing to 50.9% (R(2)?=?0.509) with the addition of age, body weight, and total dose of gonadotrophin. CONCLUSION: Ovarian response and oocyte yield after stimulation in a GnRH antagonist cycle can be predicted with high accuracy using a single determination of serum AMH before ovarian stimulation.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 1472-6483, 1472-6491
- Tipo:
- Article
- Páginas:
- 295-301
- Factor de Impacto:
- 1,171 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
REPRODUCTIVE BIOMEDICINE ONLINE ELSEVIER SCI LTD
Documentos
- No hay documentos
Filiaciones
Keywords
- Anti-Müllerian hormone; Gonadotropin-releasing hormone; Immunoassay; In vitro fertilization; Ovarian reserve; Ovarian response
Proyectos asociados
Estudio Piloto: Evaluación del sistema CRISPR/Cas9 en la edición de ADN espermático.
Investigador Principal: MARÍA JOSÉ ESCRIBÁ PÉREZ
PI19/00577 . INSTITUTO DE SALUD CARLOS III . 2020
Estudio piloto para la obtención de ovocitos maduros mediante maduración in vitro en mujeres donantes de ovocitos
Investigador Principal: ERNESTO BOSCH APARICIO
FPU18/01647 . MINISTERIO DE CIENCIA E INNOVACION . 2019
Influencia del virus del papiloma humano (VPH) en semen sobre los resultados reproductivos y lavado de semen con heparinasa como opción terapéutica en la infección.
Investigador Principal: NICOLÁS GARRIDO PUCHALT
PI21/00322 . INSTITUTO DE SALUD CARLOS III . 2022
Cita
Bosch E,Labarta E,Zuzuarregui J,Iliodromiti S,Nelson SM. Prediction of ovarian response using the automated Elecsys anti-Mullerian hormone assay in gonadotrophin-releasing hormone antagonist cycles. Reprod Biomed Online. 2022. 46. (2):p. 295-301. IF:4,000. (1).